November 24, 2016 - By Ellis Scott · 0 Comments
The stock of Aralez Pharmaceuticals Incorporated (NASDAQ:ARLZ) registered an increase of 5.78% in short interest. ARLZ’s total short interest was 4.25 million shares in November as published by FINRA. Its up 5.78% from 4.02 million shares, reported previously. With 450,800 shares average volume, it will take short sellers 9 days to cover their ARLZ’s short positions. The short interest to Aralez Pharmaceuticals Incorporated’s float is 10.53%. The stock decreased 1.51% or $0.07 on November 23, hitting $4.57. About 590,765 shares traded hands or 13.70% up from the average. Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) has risen 8.29% since April 22, 2016 and is uptrending. It has outperformed by 2.88% the S&P500.
Aralez Pharmaceuticals Inc. is a Canada specialty pharmaceutical company. The company has a market cap of $303.58 million. The Firm focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. It currently has negative earnings. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
More notable recent Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) news were published by: Fool.com which released: “Why Aralez Pharmaceuticals Inc Jumped Higher Today” on August 01, 2016, also Marketwatch.com with their article: “/quotes/zigman/3870025/realtime” published on February 12, 2016, Fool.com published: “Why Aralez Pharmaceuticals Inc. Approved a Higher Price Today” on September 15, 2016. More interesting news about Aralez Pharmaceuticals Inc (NASDAQ:ARLZ) were released by: Investorplace.com and their article: “Aralez Pharmaceuticals Inc (ARLZ) Soars on AstraZeneca Deal” published on October 04, 2016 as well as Seekingalpha.com‘s news article titled: “Aralez Pharmaceuticals Inc.: Upcoming Catalysts Create Tremendous Upside” with publication date: August 18, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ellis Scott